12-15 Molecular Diagnostics Announces Its Point Of Care Product For Potential Test For Viral Infection
The company announces its Point of Care product which can distinguish between viral and bacterial infection using biofluids. Lab test with synthetic virus shows results with high sensitivity and specificity. The company plans to partner with local Connecticut small businesses and smaller universities in screening employees and students for potential infection.
EAST HAVEN, Conn., July 6, 2020 /PRNewswire-PRWeb/ -- 12-15 Molecular Diagnostics, a point of care diagnostic start up based in East Haven, Connecticut announces today that it has developed a rapid diagnostics test device which can distinguish between viral and bacterial infection using biofluids including saliva. The lab test with synthetic virus shows promising results with high specificity and sensitivity which are comparable to the lab-based diagnostics. The total test time is less than 20 minutes.
The market release for the product is planned for Q4 of 2020 after the company receives required regulatory approval.
In the meantime, the company plans to partner with local Connecticut small businesses and smaller universities in screening employees and students for potential viral infection as these businesses and universities plan for reopening.
"This is an exciting time for our company and our team as we progress towards the market introduction of our device. Our home base is Connecticut and we are committed to helping small businesses and universities in screening employees and students now that the state has detailed its plan for reopening businesses and educational institutions," said Dr. Saion Sinha, President & CEO of 12-15 Molecular Diagnostics.
Contact:
12-15 Molecular Diagnostics (https://www.12-15mds.com/)
Dr. Saion K. Sinha
President and CEO
Email: [email protected]
Phone: 203-350- 9736
SOURCE 12-15 Molecular Diagnostics
Share this article